Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Chromatin remodeling: a novel mechanism of psychotropic drug action.

Newton SS, Duman RS.

Mol Pharmacol. 2006 Aug;70(2):440-3. Epub 2006 May 25.

2.

Chromatin as a target for the DNA-binding anticancer drugs.

Majumder P, Pradhan SK, Devi PG, Pal S, Dasgupta D.

Subcell Biochem. 2007;41:145-89. Review.

PMID:
17484128
3.

Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.

Santini V, Gozzini A, Ferrari G.

Curr Drug Metab. 2007 May;8(4):383-93. Review.

PMID:
17504226
4.

Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M.

J Cell Physiol. 2007 Aug;212(2):330-44. Review.

PMID:
17458893
5.

Epigenetic interplay between histone modifications and DNA methylation in gene silencing.

Vaissière T, Sawan C, Herceg Z.

Mutat Res. 2008 Jul-Aug;659(1-2):40-8. doi: 10.1016/j.mrrev.2008.02.004. Epub 2008 Feb 29. Review.

PMID:
18407786
6.
7.

Advances in chromatin remodeling and human disease.

Cho KS, Elizondo LI, Boerkoel CF.

Curr Opin Genet Dev. 2004 Jun;14(3):308-15. Review.

PMID:
15172675
8.

Simple histone acetylation plays a complex role in the regulation of gene expression.

Fukuda H, Sano N, Muto S, Horikoshi M.

Brief Funct Genomic Proteomic. 2006 Sep;5(3):190-208. Review.

PMID:
16980317
9.

Histone deacetylase inhibitors in cancer therapy.

Rasheed WK, Johnstone RW, Prince HM.

Expert Opin Investig Drugs. 2007 May;16(5):659-78. Review.

PMID:
17461739
10.

Chromatin-remodelling mechanisms in cancer.

Lafon-Hughes L, Di Tomaso MV, Méndez-Acuña L, Martínez-López W.

Mutat Res. 2008 Mar-Apr;658(3):191-214. doi: 10.1016/j.mrrev.2008.01.008. Epub 2008 Feb 17. Review.

PMID:
18403253
11.

Histone acetylation and chromatin signature in stem cell identity and cancer.

Shukla V, Vaissière T, Herceg Z.

Mutat Res. 2008 Jan 1;637(1-2):1-15. Epub 2007 Aug 1. Review.

PMID:
17850830
12.

Chromatin proteomics and epigenetic regulatory circuits.

Bönisch C, Nieratschker SM, Orfanos NK, Hake SB.

Expert Rev Proteomics. 2008 Feb;5(1):105-19. doi: 10.1586/14789450.5.1.105. Review.

PMID:
18282127
13.

Histone variants and complexes involved in their exchange.

Kusch T, Workman JL.

Subcell Biochem. 2007;41:91-109. Review.

PMID:
17484125
14.

Epigenetic marking and neuronal plasticity.

Duman RS, Newton SS.

Biol Psychiatry. 2007 Jul 1;62(1):1-3. Review. No abstract available.

PMID:
17572174
15.

[Epigenetics and drug addiction: a focus on MeCP2 and on histone acetylation].

Zwiller J.

Med Sci (Paris). 2015 Apr;31(4):439-46. doi: 10.1051/medsci/20153104019. Epub 2015 May 8. Review. French.

16.

Chromatin remodeling and neuronal function: exciting links.

Santos M, Coelho PA, Maciel P.

Genes Brain Behav. 2006;5 Suppl 2:80-91. Review.

17.
18.

The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy.

Lunke S, El-Osta A.

J Neurochem. 2009 Jun;109(6):1557-69. doi: 10.1111/j.1471-4159.2009.06084.x. Epub 2009 Apr 4. Review.

19.

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.

Bishton M, Kenealy M, Johnstone R, Rasheed W, Prince HM.

Expert Rev Anticancer Ther. 2007 Oct;7(10):1439-49. Review.

PMID:
17944568
20.

Epigenetic regulation of airway inflammation.

Adcock IM, Tsaprouni L, Bhavsar P, Ito K.

Curr Opin Immunol. 2007 Dec;19(6):694-700. Epub 2007 Aug 27. Review.

PMID:
17720468

Supplemental Content

Support Center